Skip to main content


  • AddRemove
  • Build a Report 
News Releases

Mayer Brown continues to expand FDA regulatory capabilities with addition of Christopher Mikson as partner in Washington DC

15 July 2015

Mr. Mikson’s arrival continues rapid growth of DC office, with more than 30 lateral hires in past 18 months

Mayer Brown announced today that Christopher Mikson has joined the firm’s Litigation & Dispute Resolution practice as a partner in Washington DC, where he will focus on federal Food and Drug Administration (FDA) regulatory matters and patent litigation. Previously, Mr. Mikson was of counsel at Jones Day.

“We are delighted to welcome Chris to the firm’s growing FDA regulatory practice,” said Mike Lackey, leader of Mayer Brown’s global Litigation & Dispute Resolution practice. “As a physician, registered patent attorney and experienced trial lawyer, Chris brings unique experience in clinical medicine, basic science and the law. His crossover skills between intellectual property, food, false advertising, medical devices and drugs add a new dimension to our preeminent litigation practice and will be of tremendous value to clients looking to navigate the complex FDA regulatory and public policy landscape.”

Mr. Mikson is the most recent addition to the firm’s FDA regulatory practice. In June, Mark Mansour also joined Mayer Brown’s DC office from Jones Day.

Mr. Mikson focuses his practice on regulatory, intellectual property, litigation and legislative matters involving health care and the life sciences. He serves clients primarily in the pharmaceutical, biotechnology, medical device and health care industries. Mr. Mikson has handled a wide range of premarket and post-market FDA matters, litigated patent and other complex cases throughout the country, conducted proceedings before the United States Patent and Trademark Office and drafted various forms of federal legislation.

“Mayer Brown presents a comprehensive platform that complements my existing FDA practice and allows me to expand my patent litigation practice by harnessing the tremendous synergies with the firm’s premier patent litigators,” said Mr. Mikson. “I look forward to collaborating closely with my new colleagues and contributing to the growth of the DC office and our regulatory and IP work.”

Mr. Mikson is a Fellow of the American College of Legal Medicine and a member of the American Intellectual Property Law Association, the American Health Lawyers Association, the Food and Drug Law Institute and the American Medical Association. He has taught patent and FDA law at the University of Pennsylvania and served on the board of trustees of the Pennsylvania Medical Society.

“Chris is a terrific addition to our growing FDA regulatory practice and DC office,” said Dan Masur, partner-in-charge of Mayer Brown’s Washington DC office.  “As companies look to expand in new areas or develop new products, Chris is a truly dynamic lawyer who can advise clients on a broad range of pressing issues.”

Mr. Mikson has spoken and written extensively on intellectual property and regulatory issues, including those pertaining to Hatch-Waxman, biosimilars and medical devices. He earned his MD from Jefferson Medical College after completing the Post Baccalaureate Premedical Program at the University of Pennsylvania. He earned his JD from Rutgers School of Law–Camden and his BA from Rutgers College.

The Build a Report feature requires the use of cookies to function properly.  Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently.  If you do not accept cookies, this function will not work.  For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.